S-8

As filed with the Securities and Exchange Commission on March 14, 2019

Registration No. 333-                

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

Sienna Biopharmaceuticals, Inc.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   27-3364627

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification Number)

30699 Russell Ranch Road, Suite 140

Westlake Village, CA

  91362
(Address of Principal Executive Offices)   (Zip Code)

2017 Incentive Award Plan

2017 Employee Stock Purchase Plan

(Full Title of the Plan)

Frederick C. Beddingfield III, M.D., Ph.D.

President and Chief Executive Officer

Sienna Biopharmaceuticals, Inc.

30699 Russell Ranch Road, Suite 140

Westlake Village, CA 91362

(818) 629-2256

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copies to:

 

Alan C. Mendelson, Esq.

Brian J. Cuneo, Esq.

Latham & Watkins LLP

140 Scott Drive

Menlo Park, CA 94025

Telephone: (650) 328-4600

Facsimile: (650) 463-2600

 

Timothy K. Andrews, Esq.

General Counsel and Secretary

Sienna Biopharmaceuticals, Inc.

30699 Russell Ranch Road, Suite 140

Westlake Village, California 91362

Telephone: (818) 629-2256

Facsimile: (818) 706-1214

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer      Accelerated filer  
Non-accelerated filer   ☐  (Do not check if a smaller reporting company)    Smaller reporting company  
    

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☒

 

 

CALCULATION OF REGISTRATION FEE

 

 

Title of Each Class of

Securities to be Registered

 

Amount

to be

Registered (1)

 

Proposed

Maximum

Offering Price

Per Share (2)

 

Proposed

Maximum

Aggregate

Offering Price (2)

 

Amount of

Registration Fee

Common Stock, $0.0001 par value per share

  847,084(3)   $2.525   $2,138,887   $259

Common Stock, $0.0001 par value per share

  211,771(4)   $2.525   $534,722   $65

Total:

  1,058,855       $2,673,609   $324

 

 

(1)

Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall also cover any additional shares of the Registrant’s common stock that become issuable under the 2017 Incentive Award Plan (the “2017 Plan”) and the 2017 Employee Stock Purchase Plan (the “ESPP”) by reason of any stock dividend, stock split, recapitalization or similar transaction effected without the Registrant’s receipt of consideration which would increase the number of outstanding shares of common stock.

(2)

Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) promulgated under the Securities Act. The proposed maximum offering price per share and the proposed maximum aggregate offering price for shares reserved for future issuance under the 2017 Plan and the ESPP are based on the average of the high and the low price of Registrant’s common stock as reported on The Nasdaq Global Select Market on March 11, 2019.

(3)

Represents the additional shares of the Registrant’s common stock available for future issuance under the 2017 Plan resulting from an annual increase as of January 1, 2019.

(4)

Represents the additional shares of the Registrant’s common stock available for future issuance under the ESPP resulting from an annual increase as of January 1, 2019.

Proposed sale to take place as soon after the effective date of the

registration statement as awards under the plans are exercised and/or vest.

 

 

 


REGISTRATION OF ADDITIONAL SECURITIES

This Registration Statement on Form S-8 is being filed for the purpose of registering additional shares of common stock, par value $0.0001 per share (the “Common Stock”) of Sienna Biopharmaceuticals, Inc. (the “Registrant”). The Registrant is hereby registering an additional 847,084 shares of Common Stock issuable under the Sienna Biopharmaceuticals, Inc. 2017 Incentive Award Plan (the “2017 Plan”) and an additional 211,771 shares of Common Stock issuable under the Sienna Biopharmaceuticals, Inc. 2017 Employee Stock Purchase Plan (the “ESPP”). The Registrant previously registered shares of its Common Stock for issuance under the 2017 Plan and the ESPP under a Registration Statement on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on August 1, 2017, (File 333-219609) and a Registration Statement on Form S-8 filed with the Commission on March 15, 2018 (File No. 333-223689) (the “Original Registration Statements”).

INCORPORATION BY REFERENCE OF CONTENTS OF

REGISTRATION STATEMENT ON FORM S-8

Pursuant to Instruction E of Form S-8, the contents of the Original Registration Statements are incorporated by reference in this registration statement on Form S-8.

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the SEC.

Item 8. Exhibits.

 

         Incorporated by Reference  

Filed

Herewith

Exhibit

Number

  Exhibit Description    Form    Date    Number
  4.1   Amended and Restated Certificate of Incorporation, as amended.    8-K    8-1-17    3.1  
  4.2   Amended and Restated Bylaws.    8-K    8-1-17    3.2  
  4.3   Form of Common Stock Certificate.    S-1/A    7-17-17    4.2  
  5.1   Opinion of Latham & Watkins LLP.            X
23.1   Consent of independent registered public accounting firm.            X
23.2   Consent of Latham & Watkins LLP (included in Exhibit 5.1).            X
24.1   Power of Attorney. Reference is made to the signature page to the Registration Statement.            X
99.1(a)#   2017 Incentive Award Plan.    S-8    8-1-17    99.2(a)  
99.1(b)#   Form of Stock Option Grant Notice and Stock Option Agreement under the 2017 Incentive Award Plan.    S-1/A    7-17-17    10.6(b)  
99.1(c)#   Form of Restricted Stock Award Grant Notice under the 2017 Incentive Award Plan.    S-1/A    7-17-17    10.6(c)  
99.1(d)#   Form of Restricted Stock Unit Award Grant Notice under the 2017 Incentive Award Plan.    S-1/A    7-17-17    10.6(d)  
99.2#   2017 Employee Stock Purchase Plan.    S-8    8-1-17    99.3  

 

#

Indicates management contract or compensatory plan.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Westlake Village, State of California, on this 14th day of March, 2019.

 

Sienna Biopharmaceuticals, Inc.
By:       /s/ Frederick C. Beddingfield III
      Frederick C. Beddingfield III, M.D., Ph.D.
      President and Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Frederick C. Beddingfield III, M.D., Ph.D., and John W. Smither and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

 

Signature    Title   Date

/s/ Frederick C. Beddingfield III

Frederick C. Beddingfield III, M.D., Ph.D.

  

President, Chief Executive Officer and Director

(Principal Executive Officer)

  March 14, 2019

/s/ John W. Smither

John W. Smither

  

Chief Financial Officer

(Principal Financial and Accounting Officer)

  March 14, 2019

/s/ Keith R. Leonard Jr.

Keith R. Leonard Jr.

  

Chairman of the Board of Directors

  March 14, 2019

/s/ Kristina Burow

Kristina Burow

  

Director

  March 14, 2019

/s/ Dennis M. Fenton

Dennis M. Fenton, Ph.D.

  

Director

  March 14, 2019

/s/ Todd Harris

Todd Harris, Ph.D.

  

Director

  March 14, 2019

/s/ James M. Hindman

James M. Hindman

  

Director

  March 14, 2019

/s/ Robert More

Robert More

  

Director

  March 14, 2019
EX-5.1

Exhibit 5.1

 

 

140 Scott Drive

Menlo Park, California  94025

Tel: +1.650.328.4600    Fax: +1.650.463.2600

www.lw.com

LOGO   FIRM / AFFILIATE OFFICES
        Beijing   Moscow
        Boston   Munich
        Brussels   New York
        Century City   Orange County
        Chicago   Paris
        Dubai   Riyadh
March 14, 2019         Düsseldorf   Rome
        Frankfurt   San Diego
        Hamburg   San Francisco
        Hong Kong   Seoul
        Houston   Shanghai
        London   Silicon Valley
        Los Angeles   Singapore
        Madrid   Tokyo
        Milan   Washington, D.C.

Sienna Biopharmaceuticals, Inc.

30699 Russell Ranch Road, Suite 140

Westlake Village, CA 91362

 

  Re:

Registration Statement on Form S-8; 1,058,855 shares of Common Stock of Sienna Biopharmaceuticals, Inc., par value $0.0001 per share

Ladies and Gentlemen:

We have acted as special counsel to Sienna Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with the registration by the Company of up to an aggregate of 1,058,855 shares of common stock of the Company, par value $0.0001 per share (the “Shares”), issuable under the Company’s 2017 Incentive Award Plan (the “2017 Plan”) and 2017 Employee Stock Purchase Plan (the “ESPP” and, together with the 2017 Plan, the “Plans”). The Shares are included in a registration statement on Form S-8 under the Securities Act of 1933, as amended (the “Act”), filed with the Securities and Exchange Commission (the “Commission”) on March 14, 2019 (the “Registration Statement”). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the related prospectus, other than as expressly stated herein with respect to the issuance of the Shares.

As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the “DGCL”), and we express no opinion with respect to any other laws.

Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers and have been issued by the Company against payment therefor in the circumstances contemplated by the Plans, assuming in


March 14, 2019

Page 2

 

LOGO

 

each case that the individual issuances, grants or awards under the Plans are duly authorized by all necessary corporate action and duly issued, granted or awarded and exercised in accordance with the requirements of law and the Plans (and the agreements and awards duly adopted thereunder and in accordance therewith), the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL.

This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

Very truly yours,

/s/ Latham & Watkins LLP

EX-23.1

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Sienna Biopharmaceuticals, Inc. 2017 Incentive Award Plan and the 2017 Employee Stock Purchase Plan of our report dated March 14, 2019, with respect to the consolidated financial statements of Sienna Biopharmaceuticals, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2018, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Los Angeles, California

March 14, 2019